Bionano Genomics, Inc.
BNGO
Rank in Stocks
#27854
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing... Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Share Price
$1.10
Last synced: 2026-11-11
Market Cap
$13.19M
Change (1 day)
-10.57%
Change (1 year)
-25.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Bionano Genomics, Inc. (BNGO)
Category
Healthcare
Operating Margin for Bionano Genomics, Inc. (BNGO)
Operating Margin as of November 2026 TTM: -106.67%
According to Bionano Genomics, Inc.'s latest financial reports, its current operating margin (TTM) is -106.67%. At the end of 2025 the company had an operating margin of -116.95%.
Operating Margin history for Bionano Genomics, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -106.67% | -8.79% |
| 2025 | -116.95% | -65.39% |
| 2024 | -337.87% | -43.31% |
| 2023 | -595.98% | 25.81% |
| 2022 | -473.70% | 10.47% |
| 2021 | -428.79% | -5.42% |
| 2020 | -453.38% | 77.49% |
| 2019 | -255.44% | 50.15% |
| 2018 | -170.12% | -30.36% |
| 2017 | -244.28% | -21.61% |
| 2016 | -311.63% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.98% | -100.17% |
US
|
|
| 20.38% | -100.19% |
US
|
|
| 43.02% | -100.40% |
CN
|
|
| 32.03% | -100.30% |
US
|
|
| 22.23% | -100.21% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Bionano Genomics, Inc.'s operating margin
What is Bionano Genomics, Inc.'s operating margin?
Bionano Genomics, Inc.'s operating margin is -106.67%, as of Nov 2026.
What was Bionano Genomics, Inc.'s operating margin in 2025?
In 2025, Bionano Genomics, Inc.'s operating margin was -116.95%, compared with -337.87% in 2024.
How has Bionano Genomics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Bionano Genomics, Inc.'s operating margin was highest in 2025 (-116.95%) and lowest in 2023 (-595.98%).
How does Bionano Genomics, Inc.'s operating margin compare with similar companies?
Bionano Genomics, Inc.'s operating margin (-106.67%) is lower than that of all 5 similar companies listed above. The highest among them is WuXi AppTec Co., Ltd., with 43.02%.